| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
RICHMOND, VA – November 5, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herein reflect the Company’s continuin... |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
1 October 29, 2026 Perry A. Bernocchi Delivered Via Email Re: Transition Agreement Dear Perry, This letter agreement (this “Agreement”) sets forth the terms of your transition from Executive Vice President, Chief Operating Officer (“COO”... |
| 02 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Richmond, VA – November 2, 2026 – Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, ... |
| 30 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders’ Equity; |
| 09 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
RICHMOND, VA – October 9, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is ... |
| 17 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth |
| 17 Aug 2026 |
8-K: Regulation FD Disclosure
RICHMOND, VA – August 17, 2026 – Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. |
| 10 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +2 more
This Section 382 Rights Agreement (this “Agreement”), dated as of August 10, 2026, is between Accendra Health, Inc., a Virginia corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as r... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CEO Ed Pesicka Announces Intention To Retire By The End of 2026 |
| 10 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
RICHMOND, VA – August 10, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, a... |
| 25 Jun 2026 |
8-K: Other Events
RICHMOND, VA – June 23, 2026 – Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the expiration and final results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company’s outstan... |
| 15 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
AMENDMENT NO. 4 TO CREDIT AGREEMENT AND CONSENT, dated as of June 15, 2026 (this “Amendment”), by and among ACCENDRA HEALTH, INC. (f/k/a OWENS & MINOR, INC.), a Virginia corporation (the “Parent Borrower”), BARISTA ACQUISITION I, LLC, a ... |
| 22 May 2026 |
8-K: Regulation FD Disclosure
RICHMOND, VA – May 22, 2026 – Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it has commenced an offer to exchange (the “Exchange Offers”) any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the... |
| 15 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On May 14, 2026 at the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Accendra Health, Inc. (the “Company”), the shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan (the “Amende... |
| 11 May 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Attention: Jonathan A. Leon, Executive Vice President & Chief Financial Officer |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction |
| 19 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Completed Sale of Products & Healthcare Services Business On December 31, 2025 |
| 31 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
Lock-Boxes, Collection Accounts and Collection Account Banks |
| 18 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Owens & Minor Announces Corporate Name Change to Accendra Health, Inc. |
| 08 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Appointment of Perry A. Bernocchi as Executive Vice President, Chief Operating Officer |
Loading...